Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07220629 · ClinicalTrials.gov registry record · Phase 2
Study to Explore the Safety and Efficacy of NT-0796 as an Adjunct to Semaglutide in Participants With Obesity (RESOLVE-2)
A Phase 2 study of Obesity, sponsored by NodThera Limited.
- Active
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
- 10
- Study locations
NCT07220629 is a Phase 2 study of Obesity that is active but no longer recruiting, run by NodThera Limited. The registered enrollment target is 80 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (90% lower). The trial reports 10 study locations across 7 states.
The verdict
NCT07220629, a Phase 2 study of Obesity, is active but no longer recruiting, sponsored by NodThera Limited.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
- 10
- Study locations
Study Summary
A Phase 2a randomized, double-blind, placebo-controlled, parallel-group, multicenter study to explore the safety and efficacy of NT-0796 as an adjunct to semaglutide in participants with obesity over a 6 months treatment period.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG NT-0796
Study Locations (10)
Florida
- Investigative Site - Cooper City
- Investigative Site - Hialeah
- Investigative Site - Jacksonville
- Investigative Site - Miami
Arizona
- Investigative Site - Mesa
Louisiana
- Investigative Site - Marrero
Ohio
- Investigative Site - Columbus
Texas
- Investigative Site - Seabrook
Utah
- Investigative Site - Salt Lake City
Virginia
- Investigative Site - Manassas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2025-10-02 |
| Est. Completion | 2026-06-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07220629
The ClinicalTrials.gov registry entry for NCT07220629 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (90% lower). The listed sponsor is NodThera Limited, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07220629 reports 10 study locations spanning 7 distinct geographic areas - top geographies include Florida, Arizona, Louisiana.
Frequently Asked Questions
What is clinical trial NCT07220629 about?
NCT07220629 is a clinical study titled "Study to Explore the Safety and Efficacy of NT-0796 as an Adjunct to Semaglutide in Participants With Obesity (RESOLVE-2)". A Phase 2a randomized, double-blind, placebo-controlled, parallel-group, multicenter study to explore the safety and efficacy of NT-0796 as an adjunct to semaglutide in participants with obesity over a 6 months treatment period.
What is the current status of trial NCT07220629?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2025-10-02. Estimated completion is 2026-06-01.
What conditions does trial NCT07220629 study?
This clinical trial studies the following conditions: Obesity.
What interventions are being tested in trial NCT07220629?
The interventions under investigation include: Placebo (DRUG), NT-0796 (DRUG).
Who is sponsoring clinical trial NCT07220629?
This trial is sponsored by NodThera Limited, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07220629 being conducted?
This trial has 10 study locations across Arizona, Florida, Louisiana, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
RECRUITING · Phase 2
-
Convergent Mechanisms Underlying Reprometabolic Syndrome in Women
RECRUITING · Phase 2
-
Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity
RECRUITING · Phase 2
-
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
RECRUITING · Phase 2
-
Pharmacological and Behavioral Treatment After Bariatric Surgery
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.